Skip to main content
IOVANCE BIOTHERAPEUTICS, INC. logo

IOVANCE BIOTHERAPEUTICS, INC. — Investor Relations & Filings

Ticker · IOVA ISIN · US4622601007 LEI · 2549002L8WT2ACU5Q878 US Manufacturing
Filings indexed 829 across all filing types
Latest filing 2026-05-01 Annual Report
Country US United States of America
Listing US IOVA

About IOVANCE BIOTHERAPEUTICS, INC.

https://www.iovance.com/

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on innovating, developing, and delivering cell therapies for cancer. The company's core technology is Tumor Infiltrating Lymphocyte (TIL) therapy, a personalized immunotherapy that harnesses a patient's own immune system. The process involves extracting T-cells from a patient's tumor, expanding them, and re-infusing them to recognize and attack cancer cells by targeting unique neoantigens. Iovance is investigating its T-cell-based therapies in clinical trials for various advanced solid tumors, such as metastatic melanoma. The company is also advancing genetically modified TIL therapies as a next-generation approach to cancer treatment.

Recent filings

Filing Released Lang Actions
ARS - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Annual Report
2026-05-01 English
DEF 14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Proxy Solicitation & Information Statement
2026-04-28 English
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Regulatory Filings
2026-03-20 English
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Director's Dealing
2026-02-26 English
10-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Annual Report FY 2025
2026-02-24 English
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Regulatory Filings
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.